<SEC-DOCUMENT>0001193125-24-022704.txt : 20240202
<SEC-HEADER>0001193125-24-022704.hdr.sgml : 20240202
<ACCEPTANCE-DATETIME>20240202132129
ACCESSION NUMBER:		0001193125-24-022704
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		6
CONFORMED PERIOD OF REPORT:	20240202
FILED AS OF DATE:		20240202
DATE AS OF CHANGE:		20240202

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Sanofi
		CENTRAL INDEX KEY:			0001121404
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				133529324
		STATE OF INCORPORATION:			I0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-31368
		FILM NUMBER:		24589948

	BUSINESS ADDRESS:	
		STREET 1:		46 AVENUE DE LA GRANDE ARMEE
		CITY:			PARIS
		STATE:			I0
		ZIP:			75017
		BUSINESS PHONE:		33153774400

	MAIL ADDRESS:	
		STREET 1:		46 AVENUE DE LA GRANDE ARMEE
		CITY:			PARIS
		STATE:			I0
		ZIP:			75017

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SANOFI-AVENTIS
		DATE OF NAME CHANGE:	20040826

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SANOFI SYNTHELABO SA
		DATE OF NAME CHANGE:	20010104
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d132037d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:20pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">6-K</FONT> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE <FONT STYLE="white-space:nowrap">13a-16</FONT> OR <FONT STYLE="white-space:nowrap">15d-16</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">For the month of
February 2024 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">Commission File Number: <FONT STYLE="white-space:nowrap">001-31368</FONT> </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>SANOFI </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">(Translation of
registrant&#146;s name into English) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">46, avenue de la Grande Arm&eacute;e, 75017 Paris, FRANCE </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">(Address of principal executive offices) </P> <P STYLE="margin-top:36pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">Indicate
by check mark whether the registrant files or will file annual reports under cover Form <FONT STYLE="white-space:nowrap">20-F</FONT> or Form <FONT STYLE="white-space:nowrap">40-F.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">Form <FONT STYLE="white-space:nowrap">20-F</FONT> &#9746;&#8195;&#8195;Form <FONT STYLE="white-space:nowrap">40-F</FONT> &#9744; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">In January and in February 2024, Sanofi published the press releases attached hereto as Exhibits&nbsp;99.1
and 99.2 which are incorporated herein by reference. </P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="89%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><B>Exhibit Index</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="32"></TD>
<TD HEIGHT="32" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:9pt; font-family:Times New Roman; ">Exhibit&nbsp;No.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:9pt; font-family:Times New Roman; " ALIGN="center">Description</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="32"></TD>
<TD HEIGHT="32" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:9pt">Exhibit&nbsp;99.1</FONT><BR></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman"><A HREF="d132037dex991.htm">Press Release dated January&nbsp;
25, 2024: Dupixent&reg; FDA approved as first and only treatment indicated for children aged 1 year and older with eosinophilic esophagitis&nbsp;(EoE) </A></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="32"></TD>
<TD HEIGHT="32" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" NOWRAP>Exhibit 99.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d132037dex992.htm">Press Release dated February&nbsp;1, 2024: <FONT STYLE="white-space:nowrap">Fran&ccedil;ois-Xavier</FONT> Roger appointed Chief Financial Officer, member of Sanofi Executive Committee </A></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">SIGNATURES </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt">


<TR>

<TD WIDTH="55%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt">Dated: February&nbsp;2, 2024</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-size:9pt">SANOFI</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">By&#8195;&#8195;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:9pt; font-family:Times New Roman">/s/ Alexandra Roger</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name: Alexandra Roger</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title: Head of Legal Corporate&nbsp;&amp; Finance</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d132037dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:14pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"><FONT STYLE="font-size:14pt"><B>Press Release</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">


<IMG SRC="g132037g82u48.jpg" ALT="LOGO">
</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="justify"><FONT COLOR="#6600ff"><I>Dupixent<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> FDA approved as
first and only treatment indicated for children aged 1 year and older with eosinophilic esophagitis&nbsp;(EoE) </I></FONT></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">Approval based on Phase 3 EoE KIDS trial showing a greater proportion of children taking Dupixent achieved
histological remission compared to placebo </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">Expanded indication marks second disease for which Dupixent is approved in children this young, underscoring the
commitment to bringing therapies to young patients with significant unmet needs </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">EoE is one of five <FONT STYLE="white-space:nowrap">FDA-approved</FONT> indications for Dupixent in the U.S. for which
type 2 inflammation is an underlying driver </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify"><B>Paris and Tarrytown, N.Y. January</B><B></B><B>&nbsp;25, 2024. </B>The U.S. Food
and Drug Administration (FDA) has approved Dupixent<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (dupilumab) for the treatment of pediatric patients aged 1 to 11 years, weighing at least 15 kg, with eosinophilic esophagitis (EoE).
Dupixent is now the first and only medicine approved in the U.S. specifically indicated to treat these patients. This approval expands the initial FDA approval for EoE in <FONT STYLE="font-family:ARIAL; font-size:10pt" COLOR="#0563c1"><U>May
2022</U></FONT><FONT STYLE="font-family:ARIAL"> for patients aged 12 years and older, weighing at least 40 kg. The FDA evaluated Dupixent for this expanded indication under Priority Review, which is reserved for medicines that represent potentially
significant improvements in efficacy or safety in treating serious conditions. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">EoE is a chronic, progressive disease driven in part by type
2 inflammation that damages the esophagus and impairs its function. EoE can severely impact a child&#146;s ability to eat, and they may experience heartburn, vomiting, abdominal discomfort, trouble swallowing, food refusal and failure to thrive.
These symptoms can adversely impact their growth and development. Continuous treatment of EoE may be needed to reduce the risk of complications and disease progression. Approximately 21,000 children under the age of 12 in the U.S. are currently
being treated for EoE with unapproved therapies. However, the actual prevalence of children with the disease is likely higher, given symptoms can be mistaken for other conditions and there are delays in diagnosis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#6600ff"><B><I>Naimish Patel, M.D. </I></B></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; margin-right:7%; font-size:10pt; font-family:Times New Roman"><I></I>Head of Global Development, Immunology and Inflammation at Sanofi<I> </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; margin-right:7%; font-size:10pt; font-family:Times New Roman"><I>&#147;Young children with eosinophilic esophagitis have significant unmet medical needs; despite existing treatment
options, 40% of these children in the U.S. under the age of 12 continue to experience symptoms of this disease. Today&#146;s approval underscores our commitment to bringing therapies to young patients with unmet needs and also brings hope to these
patients who are at a critical age where struggling to eat and maintain weight directly impacts their overall nutritional intake and development.&#148; </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">The FDA approval is based on data from the Phase 3 EoE KIDS trial with two parts
(<FONT STYLE="font-family:ARIAL; font-size:10pt" COLOR="#0563c1"><U>Part A</U></FONT><FONT STYLE="font-family:ARIAL"> and </FONT><FONT STYLE="font-family:ARIAL; font-size:10pt" COLOR="#0563c1"><U>Part B</U></FONT><FONT STYLE="font-family:ARIAL">)
evaluating the efficacy and safety of Dupixent in children aged 1 to 11 years with EoE. At 16 weeks, 66% of children who received higher dose Dupixent at tiered dosing regimens based on weight (n=32) achieved histological disease remission (<FONT
STYLE="font-family:Times New Roman">&#8804;</FONT>6 eosinophils/high power field), the primary endpoint, compared to 3% for placebo (n=29). </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="98%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g132037g73n54.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">1/5</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">
Histological remission was sustained at week 52, with 17 of 32 (53%) children treated with Dupixent in Parts A and B. Histological remission was also achieved at week 52 in 8 of 15 (53%) children
who switched to Dupixent from placebo in Part B. In addition, a greater decrease in the proportion of days with one or more signs of EoE based on Pediatric EoE Sign/Symptom Questionnaire-caregiver version
<FONT STYLE="white-space:nowrap">(PESQ-C)</FONT> was observed in children treated with Dupixent at 16 weeks compared to placebo. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#6600ff"><B><I>George D. Yancopoulos, M.D., Ph.D. </I></B></FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL">Board <FONT STYLE="white-space:nowrap">co-chair,</FONT> President and Chief
Scientific Officer at Regeneron </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; margin-right:7%; font-size:10pt; font-family:Times New Roman"><I>&#147;Young children are some of the most vulnerable patients with eosinophilic
esophagitis, or EoE, as this debilitating and progressive disease threatens their basic ability to eat. Until today, these children had no approved treatment options specifically for EoE, leaving many with unapproved medicines that failed to target
the root cause of their disease. With this approval, Dupixent becomes the first and only treatment option for EoE patients aged 1 year and older, weighing at least 15 kg. By targeting the underlying type 2 inflammation that contributes to this
disease, Dupixent has the potential to transform the standard of care for these children as it has for adults and adolescents with EoE.&#148; </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">The safety profile of Dupixent observed through 16 weeks in children aged 1 to 11 years weighing at least 15 kg was generally similar to the safety
profile of Dupixent observed through 24 weeks in adult and pediatric patients aged 12 years and older with EoE. The most common adverse events (<FONT STYLE="font-family:Times New Roman">&#8805;</FONT>2%) more frequently observed with Dupixent than
placebo were injection site reactions, upper respiratory tract infections, arthralgia (joint pain) and herpes viral infections. In EoE KIDS Part B, one case of helminth infection was reported in the Dupixent arm. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify"><B>About the Dupixent Pediatric Eosinophilic Esophagitis Trial</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">The Phase 3 randomized, double-blind, placebo-controlled trial evaluated the efficacy and safety of Dupixent in children aged 1 to 11 years, weighing at
least 15 kg, with EoE, as determined by histological, endoscopic and patient- or caregiver-reported measures. At baseline, 97% of these patients had at least one <FONT STYLE="white-space:nowrap">co-existing</FONT> type 2 inflammatory disease, such
as food allergy, allergic rhinitis, asthma and atopic dermatitis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Part A, a <FONT STYLE="white-space:nowrap">16-week,</FONT> double-blind,
placebo-controlled treatment period, enrolled&nbsp;61&nbsp;patients and evaluated the safety and efficacy of Dupixent&nbsp;in a tiered, weight-based dosing schema. The primary endpoint was histological disease remission, which&nbsp;was defined as
peak esophageal intraepithelial eosinophil count of <FONT STYLE="font-family:Times New Roman">&#8804;</FONT>6 eosinophils (eos)/high power field (hpf). Changes in caregiver-reported symptoms (proportion of days with 1 or more EoE signs [e.g.,
stomach pain, vomiting, food refusal]) were evaluated using <FONT STYLE="white-space:nowrap">PESQ-C.</FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Part B was a <FONT
STYLE="white-space:nowrap">36-week</FONT> extended active treatment period (n=47) in which eligible children from Part A in the Dupixent group continued to receive their dose level and those in the placebo group in Part A switched to Dupixent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify"><B>About Dupixent </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Dupixent, which was invented
using Regeneron&#146;s proprietary <I>VelocImmune</I><SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> technology, is a fully human monoclonal antibody that inhibits the signaling of the <FONT STYLE="white-space:nowrap">interleukin-4</FONT>
<FONT STYLE="white-space:nowrap">(IL-4)</FONT> and <FONT STYLE="white-space:nowrap">interleukin-13</FONT> <FONT STYLE="white-space:nowrap">(IL-13)</FONT> pathways and is not an immunosuppressant. The Dupixent development program has shown
significant clinical benefit and a decrease in type 2 inflammation in Phase 3 trials, establishing that <FONT STYLE="white-space:nowrap">IL-4</FONT> and <FONT STYLE="white-space:nowrap">IL-13</FONT> are key and central drivers of the type 2
inflammation that plays a major role in multiple related and often <FONT STYLE="white-space:nowrap">co-morbid</FONT> diseases. These diseases include approved indications for Dupixent, such as atopic dermatitis, asthma, chronic rhinosinusitis with
nasal polyposis (CRSwNP), prurigo nodularis and EoE.</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="98%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g132037g73n54.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">2/5</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Dupixent has received regulatory approvals in one or more countries around the world for use in
certain patients with atopic dermatitis, asthma, CRSwNP, EoE, and prurigo nodularis in different age populations. Dupixent is currently approved for one or more of these indications in more than 60 countries, including in Europe, the U.S. and Japan.
More than 800,000 patients are being treated with Dupixent globally.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Dupilumab Development Program </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Dupilumab is being jointly developed by Regeneron and Sanofi under a global collaboration agreement. To date, dupilumab has been studied across more than
60 clinical trials involving more than 10,000 patients with various chronic diseases driven in part by type 2 inflammation.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">In addition to the
currently approved indications, Regeneron and Sanofi are studying dupilumab in a broad range of diseases driven by type 2 inflammation or other allergic processes in Phase 3 trials, including chronic pruritus of unknown origin, chronic obstructive
pulmonary disease (COPD) with evidence of type 2 inflammation, and bullous pemphigoid. These potential uses of dupilumab are currently under clinical investigation, and the safety and efficacy in these conditions have not been fully evaluated by any
regulatory authority.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#6600ff"><I>About Sanofi </I></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people&#146;s lives. Our team, across
some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally,
while putting sustainability and social responsibility at the center of our ambitions.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#6600ff"><I>About Regeneron </I></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious
diseases. Founded and led for over 35 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous <FONT STYLE="white-space:nowrap">FDA-approved</FONT> treatments and product
candidates in development, almost all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases,
hematologic conditions, infectious diseases and rare diseases. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Regeneron is accelerating and improving the traditional drug development process
through our proprietary <I>VelociSuite</I><I><SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP></I><I> </I>technologies, such as <I>VelocImmune</I><I><SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP></I>,<I> </I>which uses unique
genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center, which is conducting one of the largest genetics sequencing efforts in
the world. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">For more information about Regeneron, please visit
<FONT STYLE="font-family:ARIAL; font-size:10pt" COLOR="#954f72"><U>www.Regeneron.com</U></FONT><FONT STYLE="font-family:ARIAL"> or follow Regeneron on </FONT><FONT STYLE="font-family:ARIAL; font-size:10pt" COLOR="#954f72"><U>LinkedIn</U></FONT><FONT
STYLE="font-family:ARIAL">. </FONT></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#6600ff"><I>Sanofi Media Relations </I></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"><B>Sally Bain</B><B></B>&nbsp;|&nbsp;+ 1 617 834 6026 |&nbsp;<FONT STYLE="font-family:ARIAL; font-size:8pt" COLOR="#6600ff"><U>sally.bain@sanofi.com</U></FONT><FONT
STYLE="font-family:ARIAL"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"><B>Evan Berland</B> | +1 215 432 0234 | <U><FONT STYLE="font-family:ARIAL" COLOR="#6600ff">evan.berland@sanofi.com</FONT></U><FONT
STYLE="font-family:ARIAL"> <B> </B></FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"><B>Victor Rouault</B> | + 33 6 70 93 71 40 |
<U><FONT STYLE="font-family:ARIAL" COLOR="#6600ff">victor.rouault@sanofi.com</FONT></U><FONT STYLE="font-family:ARIAL"> </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="98%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g132037g73n54.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">3/5</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#6600ff"><I>Sanofi Investor Relations </I></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"><B>Eva Schaefer-Jansen </B>| + 33 7 86 80 56 39 | <U><FONT STYLE="font-family:ARIAL" COLOR="#6600ff">eva.schaefer-jansen@sanofi.com</FONT></U><FONT
STYLE="font-family:ARIAL"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"><B>Arnaud Del&eacute;pine </B>| + 33 06 73 69 36 93 |
<FONT STYLE="font-family:ARIAL; font-size:8pt" COLOR="#6600ff"><U>arnaud.delepine@sanofi.com</U></FONT><FONT STYLE="font-family:ARIAL"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"><B>Corentine
Driancourt</B> | + 33 06 40 56 92 | <U><FONT STYLE="font-family:ARIAL" COLOR="#6600ff">corentine.driancourt@sanofi.com</FONT></U><FONT STYLE="font-family:ARIAL"> </FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"><B>Felix Lauscher</B> | + 1 908 612 7239 | <U><FONT STYLE="font-family:ARIAL" COLOR="#6600ff">felix.lauscher@sanofi.com</FONT></U><FONT STYLE="font-family:ARIAL">
</FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"><B>Tarik Elgoutni</B> | + 1 617 710 3587 | <U><FONT STYLE="font-family:ARIAL" COLOR="#6600ff">tarik.elgoutni@sanofi.com</FONT><FONT STYLE="font-family:ARIAL">
</FONT></U><FONT STYLE="font-family:ARIAL"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"><B>Nathalie Pham</B> | + 33 07 85 93 30 17 |
<U><FONT STYLE="font-family:ARIAL" COLOR="#6600ff">nathalie.pham@sanofi.com</FONT></U><FONT STYLE="font-family:ARIAL"> </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#6600ff"><I>Regeneron Media Relations </I></FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"><B>Ilana
Yellen </B>| +1 <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">914-330-9618|</FONT></FONT> <U><FONT STYLE="font-family:ARIAL" COLOR="#6600ff">ilana.yellen@regeneron.com</FONT></U><FONT STYLE="font-family:ARIAL"> </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#6600ff"><I>Regeneron Investor Relations </I></FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"><B>Vesna
Tosic </B>| + 914 847 5443 | <U><FONT STYLE="font-family:ARIAL" COLOR="#6600ff">vesna.tosic@regeneron.com</FONT></U><FONT STYLE="font-family:ARIAL"> </FONT></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:4.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #cccccc">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:7pt; font-family:ARIAL"><B>Sanofi Forward-Looking Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:ARIAL"><I>This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are
statements that are not historical facts. These statements include projections and estimates regarding the marketing and other potential of the product, or regarding potential future revenues from the product. Forward-looking statements are
generally identified by the words &#147;expects&#148;, &#147;anticipates&#148;, &#147;believes&#148;, &#147;intends&#148;, &#147;estimates&#148;, &#147;plans&#148; and similar expressions. Although Sanofi&#146;s management believes that the
expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally
beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among
other things, unexpected regulatory actions or delays, or government regulation generally, that could affect the availability or commercial potential of the product, the fact that product may not be commercially successful, the uncertainties
inherent in research and development, including future clinical data and analysis of existing clinical data relating to the product, including post marketing, unexpected safety, quality or manufacturing issues, competition in general, risks
associated with intellectual property and any related future litigation and the ultimate outcome of such litigation, and volatile economic and market conditions, and the impact that pandemics or other global crises may have on us, our customers,
suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in
the public filings with the SEC and the AMF made by Sanofi, including those listed under &#147;Risk Factors&#148; and &#147;Cautionary Statement Regarding Forward-Looking Statements&#148; in Sanofi&#146;s annual report on Form <FONT
STYLE="white-space:nowrap">20-F</FONT> for the year ended December&nbsp;31, 2022. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.</I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:7pt; font-family:ARIAL"><B>Regeneron Forward-Looking Statements and Use of Digital Media </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:ARIAL"><I>This press
release includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. (&#147;Regeneron&#148; or the &#147;Company&#148;), and actual events or results
may differ materially from these forward-looking statements. Words such as &#147;anticipate,&#148; &#147;expect,&#148; &#147;intend,&#148; &#147;plan,&#148; &#147;believe,&#148; &#147;seek,&#148; &#147;estimate,&#148; variations of such words, and
similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. These statements concern, and these risks and uncertainties include, among others, the nature,
timing, and possible success and therapeutic applications of products marketed or otherwise commercialized by Regeneron and/or its collaborators or licensees (collectively, &#147;Regeneron&#146;s Products&#148;) and product candidates being
developed by Regeneron and/or its collaborators or licensees (collectively, &#147;Regeneron&#146;s Product Candidates&#148;) and research and clinical programs now underway or planned, including without limitation Dupixent<SUP
STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (dupilumab) for the treatment of children aged 1 to 11 years with eosinophilic esophagitis (&#147;pediatric EoE&#148;); the likelihood, timing, and scope of possible regulatory approval and
commercial launch of Regeneron&#146;s Product Candidates and new indications for Regeneron&#146;s Products, such as Dupixent for&nbsp;chronic pruritus of unknown origin, chronic obstructive pulmonary disease with evidence of type 2 inflammation,
bullous pemphigoid, and other potential indications; uncertainty of the utilization, market acceptance, and commercial success of Regeneron&#146;s Products and Regeneron&#146;s Product Candidates and the impact of studies (whether conducted by
Regeneron or others and whether mandated or voluntary), including the studies discussed or referenced in this press release, on any of the foregoing or any potential regulatory approval of Regeneron&#146;s Products (such as Dupixent) and
Regeneron&#146;s Product Candidates; the ability of Regeneron&#146;s collaborators, licensees, suppliers, or other third parties (as applicable) to perform manufacturing, filling, finishing, packaging, labeling, distribution, and other steps related
to Regeneron&#146;s Products and Regeneron&#146;s Product Candidates; the ability of Regeneron to manage supply chains for multiple products and product candidates; safety issues resulting from the administration of Regeneron&#146;s Products (such
as Dupixent) and Regeneron&#146;s Product Candidates in patients, including serious complications or side effects in connection with the use of Regeneron&#146;s Products and Regeneron&#146;s Product Candidates in clinical trials; determinations by
regulatory and administrative governmental authorities which may delay or restrict Regeneron&#146;s ability to continue to develop or commercialize Regeneron&#146;s Products and Regeneron&#146;s Product Candidates; ongoing regulatory obligations and
oversight impacting Regeneron&#146;s Products, research and clinical programs, and business, including those relating to patient privacy; the availability and extent of reimbursement of Regeneron&#146;s Products from third-party payers, including
private payer healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies, and government programs such as Medicare and Medicaid; coverage and reimbursement determinations by such payers and new
policies and procedures adopted by such payers; competing drugs and product candidates that may be superior to, or more cost effective than, Regeneron&#146;s Products and Regeneron&#146;s Product Candidates; the extent to which the results from the
research and development programs conducted by Regeneron and/or its collaborators or licensees may be replicated in other studies and/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval;
unanticipated expenses; the costs of developing, producing, and selling products; the ability of Regeneron to meet any of its financial projections or guidance and changes to the assumptions underlying those projections or guidance; the potential
for any license, collaboration, or supply agreement, including </I></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="98%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g132037g73n54.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">4/5</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:ARIAL">Regeneron&#146;s agreements with Sanofi and Bayer (or their respective affiliated companies, as applicable) to be
cancelled or terminated; the impact of public health outbreaks, epidemics, or pandemics (such as the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic) on Regeneron&#146;s business; and risks associated with intellectual property of other
parties and pending or future litigation relating thereto (including without limitation the patent litigation and other related proceedings relating to EYLEA<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (aflibercept) Injection and <FONT
STYLE="white-space:nowrap">REGEN-COV</FONT><SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (casirivimab and imdevimab)), other litigation and other proceedings and government investigations relating to the Company and/or its operations,
the ultimate outcome of any such proceedings and investigations, and the impact any of the foregoing may have on Regeneron&#146;s business, prospects, operating results, and financial condition. A more complete description of these and other
material risks can be found in Regeneron&#146;s filings with the U.S. Securities and Exchange Commission, including its Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December 31, 2022 and its Form <FONT
STYLE="white-space:nowrap">10-Q</FONT> for the quarterly period ended June 30, 2023. Any forward-looking statements are made based on management&#146;s current beliefs and judgment, and the reader is cautioned not to rely on any forward-looking
statements made by Regeneron. Regeneron does not undertake any obligation to update (publicly or otherwise) any forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new information,
future events, or otherwise.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:7pt; font-family:ARIAL"><I>Regeneron uses its media and investor relations website and social media outlets to publish important information about the Company,
including information that may be deemed material to investors. Financial and other information about Regeneron is routinely posted and is accessible on Regeneron&#146;s media and investor relations website (<FONT
STYLE="font-family:ARIAL" COLOR="#444492"><U>https://investor.regeneron.com</U></FONT>) and its LinkedIn page (<FONT STYLE="font-family:ARIAL" COLOR="#444492"><U>https://www.linkedin.com/company/regeneron-pharmaceuticals</U></FONT>).</I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="98%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g132037g73n54.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">5/5</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR></TABLE>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>d132037dex992.htm
<DESCRIPTION>EX-99.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right"><B>Exhibit 99.2 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:14pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:14pt; font-family:ARIAL"><B>Press Release</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">


<IMG SRC="g132037g0202180941113.jpg" ALT="LOGO">
</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="justify"><FONT COLOR="#6600ff"><I><FONT STYLE="white-space:nowrap">Fran&ccedil;ois-Xavier</FONT> Roger appointed Chief
Financial Officer, member of Sanofi Executive Committee </I></FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify"><B>Paris, February</B><B></B><B>&nbsp;1, 2024</B>. <FONT
STYLE="white-space:nowrap">Fran&ccedil;ois-Xavier</FONT> Roger will be appointed Chief Financial Officer and a member of Sanofi&#146;s Executive Committee effective April&nbsp;1, 2024. He will be based in Paris and will succeed Jean-Baptiste
Chasseloup de Chatillon who will step down from his role to become Head of <I>Apprentis</I><I> </I><I>d</I><I>&#146;</I><I>Auteuil</I>. <I>Apprentis</I><I> </I><I>d</I><I>&#146;</I><I>Auteuil</I> is a foundation that supports adolescents who are
struggling in life by providing education, training and integration programs, in France and internationally. Being active in charity work for many years, Jean-Baptise decided to devote the next stage of his career to giving back to society. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify"><FONT STYLE="white-space:nowrap">Fran&ccedil;ois-Xavier</FONT> will join from Nestle, where he has been the CFO for more than 8 years, providing strong
financial leadership and driving sustainable value creation. He is a seasoned executive who has lived and worked in Europe, the U.S, Asia, Africa and Latin America. Before Nestl&eacute;, Fran&ccedil;ois-Xavier&nbsp;was the CFO of Takeda
Pharmaceuticals, based in Japan, from 2013 to 2015. <FONT STYLE="white-space:nowrap">Fran&ccedil;ois-Xavier</FONT> started his career in pharma, spending the first 14 years at Roussel, Hoechst and Aventis, in various countries. From 2000 to 2008, <FONT
STYLE="white-space:nowrap">Fran&ccedil;ois-Xavier</FONT> was the CFO for Danone Asia, after which he was Head of Finance, Treasury and Tax for the Danone Group. Between 2008 to 2013, he was CFO of Millicom, a NASDAQ listed, global mobile phone
operator. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><FONT COLOR="#6600ff"><B><I>Paul Hudson </I></B></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL" ALIGN="justify">Chief Executive Officer, Sanofi </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;As we enter the next phase of launch and growth, it&#146;s a pleasure to welcome onboard
<FONT STYLE="white-space:nowrap">Fran&ccedil;ois-Xavier</FONT> Roger, a CFO with a proven track record in accelerated value creation. Since joining in 2018, Jean-Baptiste de Chatillon has been instrumental in progressing our Play to Win Strategy.
Under his leadership, our finance organization has been modernized into a team that supports our mission and execution of our strategy on a daily basis. We are proud of Jean-Baptiste&#146;s next step.&#148; </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><FONT COLOR="#6600ff"><B><I>Jean-Baptise Chasseloup de Chatillon </I></B></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Over these last 5 years, I have been privileged to witness the incredible transformation of Sanofi into a company with a strong
long-term growth potential. My decision to head Apprentis d&#146;Auteuil was also fuelled by my growing passion for the impact Sanofi has around the world. I thank Paul and all my colleagues at Sanofi for their trust over the years and will be
applauding them as they continue to drive forward our strategy.&#148; </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><FONT COLOR="#6600ff"><B><I><FONT
STYLE="white-space:nowrap">Fran&ccedil;ois-Xavier</FONT> Roger </I></B></FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;It is with great enthusiasm that I join Sanofi in
this dynamic moment marked by significant transformation. I am excited by the opportunity to further improve patient outcomes and deliver increased shareholder value in the years to come.&#148; </I></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:4.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #cccccc">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#6600ff"><I>About Sanofi </I></FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">We are
an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people&#146;s lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the
impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="98%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g132037g73n54.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">1/2</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#6600ff"><I>Media Relations </I></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"><B>Sandrine Guendoul</B><B></B>&nbsp;|&nbsp;+ 33 6 25 09 14 25
|&nbsp;<FONT STYLE="font-family:ARIAL; font-size:8pt" COLOR="#6600ff"><U>sandrine.guendoul@sanofi.com</U></FONT><FONT STYLE="font-family:ARIAL"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"><B>Nicolas
Obrist</B><B></B>&nbsp;|&nbsp;+ 33 6 77 21 27 55 |&nbsp;<FONT STYLE="font-family:ARIAL; font-size:8pt" COLOR="#6600ff"><U>nicolas.obrist@sanofi.com</U></FONT><FONT STYLE="font-family:ARIAL"> </FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"><B>Victor Rouault</B><B></B>&nbsp;|&nbsp;+ 33 6 70 93 71 40 |&nbsp;<FONT STYLE="font-family:ARIAL; font-size:8pt" COLOR="#6600ff"><U>victor.rouault@sanofi.com</U></FONT><FONT
STYLE="font-family:ARIAL"> </FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#6600ff"><I>Investor Relations </I></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"><B>Eva Schaefer-Jansen</B><B></B>&nbsp;|&nbsp;+ 33 7 86 80 56 39
|&nbsp;<FONT STYLE="font-family:ARIAL; font-size:8pt" COLOR="#6600ff"><U>eva.schaefer-jansen@sanofi.com</U></FONT><FONT STYLE="font-family:ARIAL"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"><B>Arnaud
Del&eacute;pine</B><B></B>&nbsp;|&nbsp;+ 33 6 73 69 36 93 | <FONT STYLE="font-family:ARIAL; font-size:8pt" COLOR="#6600ff"><U>arnaud.delepine@sanofi.com</U></FONT><FONT STYLE="font-family:ARIAL"> </FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"><B>Corentine Driancourt</B><B></B>&nbsp;|&nbsp;+ 33 6 40 56 92 21 |
<FONT STYLE="font-family:ARIAL; font-size:8pt" COLOR="#6600ff"><U>corentine.driancourt@sanofi.com</U></FONT><FONT STYLE="font-family:ARIAL"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"><B>Felix
Lauscher</B><B></B>&nbsp;|&nbsp;+ 1&nbsp;908&nbsp;612 7239 | <FONT STYLE="font-family:ARIAL; font-size:8pt" COLOR="#6600ff"><U>felix.lauscher@sanofi.com</U></FONT><FONT STYLE="font-family:ARIAL"> </FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"><B>Tarik Elgoutni|</B> + 1 617 710 3587 | <FONT STYLE="font-family:ARIAL; font-size:8pt" COLOR="#6600ff"><U>tarik.elgoutni@sanofi.com</U></FONT><FONT
STYLE="font-family:ARIAL"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"><B>Nathalie Pham</B><B></B>&nbsp;|&nbsp;+ 33 7 85 93 30 17 |
<FONT STYLE="font-family:ARIAL; font-size:8pt" COLOR="#6600ff"><U>nathalie.pham@sanofi.com</U></FONT><FONT STYLE="font-family:ARIAL"> </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="98%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g132037g73n54.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">2/2</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR></TABLE>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g132037g0202180941113.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g132037g0202180941113.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  I )(# 2(  A$! Q$!_\0
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M>T^'FK:A:Z/;6]U:Q!XI(EVD'<!_6N7_ &>O%^G65A?^';VXC@G>X^T6YD;
MDRH5@#ZC:#^->A_%W4+-/A?KD;74(>6%51=XRQWKP* /%?V>/^2DR_\ 8/E_
M]"2MO]I7_D-Z#_U[2_\ H0K$_9X_Y*3+_P!@^7_T)*V_VE?^0WH/_7M+_P"A
M"@#?^"7@KPYJO@*/4]0TJWNKN2XD5I)5W< X KG?CSX%T3P]9Z;J^D6J6C3S
MF"6*/A6^7(..QX->@? /_DEUO_U]3?\ H58O[27_ "*&D?\ 7_\ ^TVH 9^S
M;<ROX8UFW9B8XKQ60>A9.?\ T$5X[\2-9N?$_P 2=4D+,X6Z-K;KG@*C;0!]
M<9_&O7?V:O\ D!:]_P!?,?\ Z":\:\;6-QX<^).K1.I#PW[3QY'WE+;U/Y$4
M ?3'AKX1>%=$T2&TNM,@O;HQCSYYEW%FQSCT%>&_&KP%9>#-=L[C2T,=A?HQ
M6+.?+=2-P'M\P/YU]*>'/%FD>)M%M]2L;R$I(@9T+@-&W=2.Q%> ?M ^*[#6
M]<T[2M/G2==/1S-(ARN]\?+GV"_K0!ZG\#M=FUOX;6ZW+EYK&9K3<3R5 !7\
M@P'X5\U^&K>&[^(^EV]Q&LD,NJ1HZ,,AE,@!!KZ*^ .ERZ?\-EN)E*_;KJ2=
M ?[N @/_ (Z:^>O"7_)3]&_["T7_ *-% 'UU:>"_#5C=Q7=KHEG#<1-NCD2,
M J?45\X?M _\E.;_ *\H?_9J^K*^4_V@?^2G-_UY0_\ LU '1:!_R+FE_P#7
MI%_Z **- _Y%S2_^O2+_ - %% &E!\/?%2>.4F,3A%N_.-[O&W;NSNSZX[5[
MQ245W8W'U,6X^T27*K:&U:O*K;FZ'S'XT^#_ (NU;QSJ][IFCQK8W%TSQ,)X
MU&#_ !8SQGK7T%?^&K+6/"7_  C^IIYUNUND+D=05 PP/8@C-;5%<)B?*WB3
MX#^*])O';28TU2TW9C>)PL@';*D]?IFL:+X3?$"_E5'T6ZZXW3R*H'YFOL*B
M@#Q[X2?"34_!>LRZUJ]U!Y[V[0);PDMMR022W3^'M47QN\!>(O&&I:1/HEFM
MREO#(DF954J201U(KV:B@#A_A)X<U/PMX"@TW5H!#=B>1R@<-@$\<CBLOXU^
M$=9\8>&]/M=%MA<307?F.AD5<+L89Y([FO3** /+?@CX-UOP?I&JPZW:K;R7
M$Z-&HD5\@+@G@GUJY\3_ (56WCR)+VTE2UUB%-B2,/DE7LK8_0UZ-10!\?W/
MPB\?Z;</#'H]PX/&^VE#*P_ _P ZZ?P;\ =:O[Z*X\2[;"Q4[GA5PTL@]..%
M^I_*OIFB@"*TM8+&SAM+6)8K>%!''&HP%4#  KYG\/?"'QI8^/=-U&XTQ$M(
M-12:23[0A 0/DG&<]!7T[10 M> _&#X:>*?%/CC^T](T];BU-K''N\Y%PPSD
D8)%>^T4 >/Z/\/O$%MHEA!-!"LL5M&CKYHX(4 BBO8** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g132037g73n54.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g132037g73n54.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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%?2@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g132037g82u48.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g132037g82u48.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M_:JU/5);K0-(^%WAC2_,S;Z3'X:U'5W2('Y4N=0U'6S)<28QN>..W!.2$7H
M#ZP_9K_X+*PZ_P"(-*\)_M(^$=&\,VFIW$%E'\1_!OV^/1],GF;RTG\2>'+^
MXO)[?3=[)YE[97<ODC+-:% SH ?N];7-M>VUO>6=Q!=V=W!%<VMU;2QSVUS;
M3QK+!<6\\3,DT$D3*Z2(Q5E8$$@@T ?PM6?C74?!/QF@^(EO:6.L:MX4^)0\
M8V]GK,<MQIVHZEHOB;^V(8M3BBECDFM9KJV42JLB,RLP# G-&WR#;Y'[1?L[
M?\%:/CK\6?CI\*OAEXB\!_"VST+QWXVT3POJ5UI-GXHM]2M;75[I;1KBQFN_
M$ES"+B(R*ZB2"16V;2!NW  ]G_;P_P""D'Q=_9>^.G_"K? _@[X>ZQHT'@_P
M]XA:_P#$]KK]UJ3WVKR:CYJJ=-URRABMXTM8E1?*9L[V+G<%03MMH&WD>Q^!
M/V[O'7B;P/X-\1ZAX(\*1W_B#PIX=UN]2TO-7AM4O-5TBSO[E;:*665XK=9I
MW"(\LK*H +L06(!_.'^T7#JNE_M._&5?']E?7=_!\9O&ESXALIIY+6[O[63Q
M;?7<D<%TP9H8[K39$-O,H91%/"Z KMH _HP^"/Q?_P""8/Q;\(:1X2\/^&_@
M7X5,]C#9MX$^(W@OPQX=UVWE,2AK1]3\061BUR]W$J;JUU2]DE8%C(6:C] _
M0]*\*_\ !-W]ESPI\:_"'QY\"Z)J6AW'AFXDUO2_"&G:NNH> KG6F@*Z3K\%
MI?QW-U;26,LAN[>&TOH[43QV\BQ*(MKFWR#;Y'R[_P %I_BAJ_AGX.?#3X7Z
M7=26EK\2O%>J:GXA$+LAO='\#6VFW%OIDX!P]K)K6N:9=E?^>FD0GH.3] _0
M^7?^"3?[&_PR^,FF>-/C5\6O#MGXRTSPWXCC\'^$/"VKQF?0&U6VTVRU?6=:
MU?3R?+U8Q0:II=O;6]P'@5FNGDBD<0M" ?H-_P %!/V:?V?M+_9/^+WB[1O@
MY\._#WBCPGX>L-0\/:]X<\*Z1X=U33+I=?T>V+1W>C6ML\L3V\TL;Q2F2-U<
M[E) (/T#]#\I/^"-?_)V^J_]D=\9?^G[P;0![5_P7 _Y*'\!?^Q,\8?^GS2J
M /I?_@E5^S[\#_%O[+^F^.O%OPH\!^*_%VI>,O%]G>:]XH\-:7XAOFM--O8;
M:RM86UBVN%M;>*%<".%8P69G8%F)(!\Z_P#!7S]F7X._"_PW\-?BI\-O!NC>
M!-9UWQ7?>$?$6F^&+&#2="U:!]'NM8L=1;2+14M;/4;:33[B(RV\41F2\'F[
MC!&5 /;O^"(NJ7T_PB^-&C2SR/IVF_$71K^SMV8E+>YU7PW'!?/&I.$\U-)L
M<XQDQ9H _'']L;X@>(/CK^UQ\5=2EFENY9_B)?> /"EK-(?*L]%\.:L_A3P_
M9P+RMO'*MJ+F0( #/?7$I!:1B3] _0_IS^"?[!7[-?PB^'FC>#[GX5>!O&VM
MKI5K#XJ\6^,/#>E^)-8\1:NT(.I7GVC6+6<Z=8M=--]GL[7R8H(MB@,X>20V
M^0;?(_"?_@JA^R=X%_9S^(_@KQ3\+]+7P_X)^*6GZW(_AB"2233] \2^&Y].
M&III/G.SVVE7EGK.GS1VI9EAEANEC*PM%%" ?KU_P2=^*.K?$?\ 9'T/3=;N
MY;V_^&/BC6_AW!<SL7F?1+"VTS6] A=SU2STS78=/B'\,.FPKVH_0/T/YQ/@
M5ING:Q^UM\*M)U>PLM4TK4OCYX4L-1TS4;:&]T^_L;KQU9P75G>V=PCQ7-K-
M"[QR12*RNKE6!!H _L5T;X%?!+PWJMCKOA_X/_"_0M;TN<76FZOI'@+PMINI
MZ?<J&5;BROK/2HYK6<*S /$ZL-QP>:-O(-O(_FD_X+!_\GA7'_9,O!'_ *'K
M5 'T3\(O^23_  P_[)YX*_\ 4;TV@#[C_:J_9>_8Y_:Q^(3:)?\ Q&T3P1^T
M#$$T9M5\*ZIIDNJZK<64(CMM(\2Z'<N+37M0M88Q$D23VNHHD2P&;RX4B3ZF
M7!'%]/(UQ)/AS'QR)P518UX:I['V3=E5O:ZHOI5:5-JS4K.YZ3R;-8X-9@\O
MKQP5N;VWLY<G+TE>WP?WK<OF?E-\9?\ @D%^TE\.[2^UCP!?>&_C%H]G'+.;
M3P^\VA^+V@C.28_#>K,8;R;9R(+'4KN9S\L<3,0*^6/-/"?V2?VV/B_^R?X]
MTO3+W5]>U7X80ZNFF>.?AEKLMW+;V-DMTMKJMSH5C?9D\.>); )*Z+ (%EDM
M_(NXW1CL-@V/U0_X+2^"[KQ3\(/@G\6=#C:_T/POXCU;3-0O+92\<.F^/]*T
MJ\T?49"!^[LWN?#L< D.!YFHVZ=9%! /%_\ @D5^UI\,_AEHWC7X%_$_Q/I?
M@LZ[XHC\9>"M>U^ZBT[0KV^OM-T_1=9T&\U:Y9+?3+L+I.F7%L;F2..;S;I!
M(LB1),;>0;>1^A?_  4/^-GP>D_9%^,7AVV^*/@&]U_Q-X?L-.\/Z'IOBS1-
M3U?5[QM?T>X$5CIVGWLUQ,%MX)I6D$>Q$B9G8*,T ?D)_P $:_\ D[?5?^R.
M^,O_ $_>#: /:O\ @N!_R4/X"_\ 8F>,/_3YI5 'WO\ \$BO^3,_#W_8]^//
M_3I'0!XI_P %M?\ DA?PC_[*S)_ZA_B"@#GO^"('_)-OCM_V/'A3_P!,-]0!
M^//[7'@C7_@;^UO\5],G@DMKG3?B;J/CCPU//$RQ7>C:[K#>+?#EY$?NS1?9
M;VWB<HQ EMYHR0\;  ']4'P._;,^ /QN^'^C>--+^)'@WP_?SZ;;3>)/"OB/
MQ)I.AZYX6U40*=1T^_LM5NX)'MX;D2K'>QJ]O/&JRQR$-P ?@W_P5E_:B\!?
M';XC^!/ WPRURT\4>&?A58:\=2\3:8XGT?5/%'B:;3!>VND7BY34K'3['1+)
M#>0DPR37EPD;.L D< _5;_@DE\-M5\ ?LCZ7J^L6LMG<_$SQCX@\>V4$ZE)1
MH<UOI?AW1K@QGD1W=MX>-[$W\<%] XX<9 /YW/V>/^3QO@[_ -G#>#/_ %/[
M&@#^UV@#^4__ (+!_P#)X5Q_V3+P1_Z'K5 'T3\(O^23_##_ +)YX*_]1O3:
M /==+_X)]?&RS^/%GK<NJ:-_PAEGXYA\3?\ ":KK"-J4NGVVLKJR,NE?\?JZ
M^Z(HP4\E9SN^T%!O/]NXKZ0G U7@2MA88;%?VW6RF6 _LMX;]Q&M+"?5&GB;
M^Q>$BWSJR]HZ:4/9*6W['4X[R:62RI*G5^N2PKH?5O9^XINE[+^)?D]DM]/>
MY=.5,_;*OXB/QP_G9_:5_P""6?[27Q@_:&^*GQ(\,3_"K2O"OC?QQ?ZWI@NO
M$NK6U[#IU[)$#?7UA!X:D"ZA+B2YN(TF?=-++M=MP8@'[KZQ\)?!_BOX2?\
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20 4 % !0 4 % !0 4 % '__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
